Keeping a home clean requires more than just basic sweeping and dusting. Modern households face daily challenges such as pet hair, food crumbs, dust buildup, muddy footprints, and stubborn floor stains. In 2026, vacuum cleaners have become smarter and more efficient, helping homeowners save time while maintaining cleaner and healthier living spaces. Advanced cleaning technology [...]
One company posted eight straight quarters of rising revenue while the other faced sharp swings. Recent results reveal how their financial paths have diverged.
CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
Chairman and Chi
Canadian Solar (NASDAQ:CSIQ) reported first-quarter 2026 revenue at the high end of its forecast and a stronger-than-expected gross margin, helped by tariff refund accruals, while the company still posted a net loss amid higher operating costs, foreign exchange losses and tax expense accruals.
Exec
Bitdeer Technologies Group (NASDAQ:BTDR) reported sharply higher first-quarter revenue as its Bitcoin mining output expanded, while management emphasized a broader push into AI cloud services and large-scale data center colocation.
On the company’s first-quarter 2026 earnings call, Chief Strategy O
Cellebrite DI (NASDAQ:CLBT) reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives highlighted a wave of new product launches centered on artificial intelligence, cloud-based case manage
Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy.
Chief Executive Officer Dr. Christian Itin said the company h
BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quarter revenue and a narrower net loss.
On the company’s first-
Aebi Schmidt (NASDAQ:AEBI) reported higher first-quarter 2026 order intake, sales and profitability, with management pointing to strong demand in Europe and the rest of the world, improving walk-in van activity in North America and a record backlog that supports its full-year outlook.
The company s
Chime Financial delivered its first profitable quarter as revenue growth, margin expansion, and loan growth strengthened the fintech’s future prospects.
